Aprea Therapeutics Inc.

NASDAQ: APRE · Real-Time Price · USD
1.71
0.02 (1.18%)
At close: Aug 15, 2025, 3:59 PM
1.67
-2.54%
After-hours: Aug 15, 2025, 07:38 PM EDT

Aprea Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
678.55K 1.12M 1.5M 1.31M 1.28M 963.8K 583.23K 569.16K 249.69K n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost of Revenue
16.89K 16.77K 22.92K 16.45K 16.45K 11.14K 5.4K 410.00 61.78K 125.47K 188.83K 254.82K 262.9K 259.44K 271.68K 205.69K 136.24K 76K
Gross Profit
819.3K 1.26M 1.48M 1.29M 1.26M 952.66K 577.84K 568.75K 187.91K -125.47K -188.83K -254.82K -262.9K -259.44K -271.68K -205.69K -136.24K -76K
Operating Income
-14.8M -15.26M -14.32M -14.77M -14.19M -14M -15.46M -14.4M -15.1M 41.97M 38.37M 33.23M 28.03M -35.39M -37.37M -43.84M -46.64M -51.13M
Interest Income
1.01M 1.21M 1.29M 1.32M 1.3M 1.25M 1.22M 1.16M 986.84K 703.11K 446.7K 206.94K 55.82K 3.33K 3.33K 0.00 0.00 0.00
Pretax Income
-13.85M -14.08M -12.96M -13.51M -12.93M -12.72M -14.29M -13.29M -14.11M -109.11M -112.66M -117.98M -123.4M -35.4M -37.13M -44.76M -47.63M -53.75M
Net Income
-13.85M -14.08M -12.96M -13.51M -12.93M -12.72M -14.06M -121.4M -122.37M -217.42M -221.21M -118.18M -123.46M -35.4M -37.13M -44.76M -47.63M -53.75M
Selling & General & Admin
6.04M 6.29M 6.45M 7.01M 7.13M 6.98M 8.42M 8.9M 10.27M 24.2M 24.82M 26.07M 26.4M 14.11M 13.55M 15.08M 15.14M 15.58M
Research & Development
9.6M 10.25M 9.36M 9.05M 8.33M 7.97M 7.63M 6.11M 5.11M 9.72M 12.55M 16.48M 21.38M 21.22M 23.9M 28.76M 31.51M 35.55M
Other Expenses
-360.05K -360.05K -360.05K -354.62K -319.47K -319.47K -319.47K -319.47K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Operating Expenses
15.28M 16.17M 15.45M 15.71M 15.13M 14.38M 15.48M 14.45M 15.13M 33.92M 37.37M 42.55M 47.78M 35.33M 37.45M 43.84M 46.64M 51.13M
Interest Expense
n/a n/a n/a n/a n/a n/a n/a 297.54K 448.67K 501.16K 503.13K 208.91K 57.82K 5.92K 5K 6.42K 15.6K 17.69K
Selling & Marketing Expenses
n/a -5.3K -11.46K -16.45K -16.45K -11.14K -4.99K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
15.28M 16.19M 15.47M 15.72M 15.15M 14.39M 15.49M 14.45M 15.13M 33.92M 37.37M 42.55M 47.78M 35.33M 37.45M 43.84M 46.64M 51.13M
Income Tax Expense
n/a -5 -5 -5 -5 n/a -229.23K 108.11M 108.26M 108.31M 108.55M 208.91K 79.73K 27.24K 25.27K 21.94K 83.78K 83.78K
Shares Outstanding (Basic)
6.08M 5.99M 5.95M 5.94M 5.94M 4.2M 3.74M 3.74M 3.73M 3.26M 132.76K 1.73M 1.13M 1.1M 1.08M 1.06M 1.06M 1.06M
Shares Outstanding (Diluted)
6.08M 5.99M 5.95M 5.94M 5.94M 4.2M 3.74M 3.74M 3.73M 3.26M 132.76K 1.73M 1.13M 1.1M 1.08M 1.06M 1.06M 1.06M
EPS (Basic)
-2.32 -2.37 -2.38 -2.81 -3.03 -3.32 -3.92 -837.43 -838.98 -924.87 -930.85 -103.62 -110.11 -33.03 -34.91 -42.24 -44.97 -50.8
EPS (Diluted)
-2.32 -2.37 -2.38 -2.81 -3.03 -3.32 -3.92 -837.43 -838.98 -924.87 -930.85 -103.62 -110.11 -33.03 -34.91 -42.24 -44.97 -50.8
EBITDA
-14.79M -15.24M -14.3M -14.52M -13.95M -13.76M -14.99M -14.17M -14.61M -33.34M -36.84M -41.91M -47.33M -35.14M -36.85M -44.5M -47.37M -53.5M
EBIT
-14.49M -15.1M -14.32M -14.54M -13.96M -13.77M -15.24M -14.45M -15.13M -33.92M -37.37M -42.55M -47.78M -35.33M -37.45M -43.84M -46.64M -51.13M
Depreciation & Amortization
16.29K 21.59K 22.32K 21.88K 17.88K 12.8K 7.05K -319 59.62K 123.09K 186.44K 254.82K 262.9K 259.44K 271.68K 262.58K 249.82K 237.84K